卵巢癌中miR-144-3p和SGK3的表达水平及临床意义

Expression Levels and Clinical Significance of MiR-144-3p and SGK3 in Ovarian Cancer

目的检测卵巢癌中microRNA-144-3p(miR-144-3p)与血清和糖皮质诱导蛋白激酶(SGK3)的表达水平,并探究其临床意义。方法收集2010年3月～2012年7月于笔者医院经手术切除的64例上皮性卵巢癌组织、12例卵巢良性肿瘤组织和12例正常卵巢组织。实时定量PCR(qRT-PCR)技术检测卵巢癌组织miR-144-3p水平;蛋白质印迹(Western blot)法技术检测卵巢癌组织SGK3水平;分析卵巢癌组织miR-144-3p、SGK3表达与患者临床病理特征及预后的关系。结果 (1)卵巢癌组织miR-144-3p表达水平显著低于正常卵巢组织、卵巢良性组织(P <0. 05)。(2)卵巢癌组织SGK3蛋白表达水平显著高于正常卵巢组织、卵巢良性组织(P <0. 05)。(3)卵巢癌组织中miR-144-3p表达水平与SGK3蛋白表达水平显著呈负相关(P <0. 05)。(4)卵巢癌组织miR-144-3p、SGK3表达水平与患者的肿瘤直径、病理分期、淋巴结转移情况、分化程度有关(P <0. 05),与患者的年龄、有无腹腔积液、组织学类型无关(P> 0. 05)。(5)全部患者的中位生存期为40个月,术后1、3、5年的累积生存率分别为76. 56%、53. 13%、25. 00%。miR-144-3p低表达患者术后1、3、5年的累积生存率分别为67. 57%、37. 84%、10. 81%; miR-144-3p高表达患者术后1、3、5年的累积生存率分别为88. 89%、74. 07%、44. 44%;两者生存率的差异有统计学意义(P=0. 001)。(6) SGK3高表达患者术后1、3、5年的累积生存率分别为68. 29%、39. 02%、9. 76%; SGK3低表达患者术后1、3、5年的累积生存率分别为91. 30%、78. 26%、52. 17%;两者生存率的差异有统计学意义(P=0. 000)。结论 miR-144-3p、SGK3表达异常与上皮性卵巢癌的发生、发展有关,可能成为上皮性卵巢癌临床治疗及预后的新靶点。

Objective To detect the expression levels of microRNA-144-3p （miR-144-3p） and protein kinase （SGK3） induced by serum and glucocorticoid in ovarian cancer, and to explore its clinical significance. Methods From March 2010 to July 2012 we selected sixty-four cases of epithelial ovarian cancer tissues, twelve cases of benign ovarian tumors tissues and twelve cases of normal ovarian tissues resected by operation in our hospital. We detected the miR-144-3p levels in ovarian cancer tissues by real-time quantitative PCR （qRT-PCR）; detected the SGK3 levels in ovarian cancer tissues by Western blot; analyzed the relationship between the miR-144-3p, SGK3 expressions and clinicopathological features and prognosis in ovarian cancer tissue. Results （1）The expression level of miR-144-3p in ovarian cancer tissue was significantly lower than that in normal ovarian tissue and benign ovarian tissue （ P 〈0.05）. （2）The expression level of SGK3 protein in ovarian cancer tissue was significantly higher than that in normal ovarian tissue and benign ovarian tissue （ P 〈0.05）. （3）The expression level of miR-144-3p in ovarian cancer tissues was negatively correlated with the expression level of SGK3 protein （ P 〈0.05）. （4）The expression levels of miR-144-3p and SGK3 in ovarian cancer tissues were related to tumor size, pathological stage, lymph node metastasis and differentiation degree （ P 〈0.05）, but not related to age, ascites or histological type （ P 〉0.05）. （5）The median survival time was 40 months, and the cumulative survival rates at 1, 3 and 5 years after surgery were 76.56%, 53.13% and 25.00% respectively. The cumulative survival rates of patients with low expression of miR-144-3p at 1, 3 and 5 years after operation were 67.57%, 37.84% and 10.81% respectively. The cumulative survival rates of patients with high expression of miR-144-3p at 1, 3 and 5 years after operation were 88.89%, 74.07% and 44.44% respectively. The difference of survival rate between the two groups was significant （ P =0.001）. （6）The cumulative survival rates of patients with high expression of SGK3 at 1, 3 and 5 years after operation were 68.29%, 39.02% and 9.76% respectively. The cumulative survival rates of patients with low expression of SGK3 at 1, 3 and 5 years after operation were 91.30%, 78.26% and 52.17% respectively.The difference of survival rate between the two groups was significant （ P =0.000）. Conclusion The abnormal expressions of miR-144-3p and SGK3 are related to the occurrence and development of epithelial ovarian cancer, and may be a new target for the clinical treatment and prognosis of epithelial ovarian cancer.